Cassava Sciences, Inc. (NASDAQ:FLNA – Get Free Report) CEO Richard Barry acquired 44,851 shares of the business’s stock in a transaction that occurred on Wednesday, November 18th. The shares were purchased at an average price of $0.52 per share, with a total value of $23,322.52. Following the completion of the acquisition, the chief executive officer owned 1,955,947 shares of the company’s stock, valued at $1,017,092.44. This represents a 2.35% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Richard Barry also recently made the following trade(s):
- On Wednesday, September 30th, Richard Barry purchased 100,000 shares of Cassava Sciences stock. The shares were bought at an average cost of $0.92 per share, for a total transaction of $92,000.00.
- On Tuesday, September 29th, Richard Barry bought 206,813 shares of Cassava Sciences stock. The stock was purchased at an average price of $0.90 per share, for a total transaction of $186,131.70.
- On Monday, September 28th, Richard Barry acquired 93,091 shares of Cassava Sciences stock. The stock was bought at an average price of $0.84 per share, with a total value of $78,196.44.
Cassava Sciences Stock Performance
Shares of NASDAQ FLNA opened at $0.56 on Friday. The stock’s fifty day moving average is $0.69 and its 200 day moving average is $1.27. Cassava Sciences, Inc. has a 52 week low of $0.39 and a 52 week high of $3.45.
Cassava Sciences (NASDAQ:FLNA – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.22) EPS for the quarter.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings lowered shares of Cassava Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Cassava Sciences presently has a consensus rating of “Hold” and a consensus price target of $5.00.
Read Our Latest Stock Report on FLNA
About Cassava Sciences
Cassava Sciences, Inc. is a biotechnology company focused on developing treatments and diagnostic tools for Alzheimer’s disease. The company’s Nasdaq ticker is SAVA; FLNA does not correspond to Cassava Sciences. Its research has included simufilam, an investigational oral drug candidate studied for Alzheimer’s, and SavaDX, a blood-based diagnostic program. These are products under development, not approved treatments or tests. Founded in 1998 as Pain Therapeutics, the company adopted the Cassava Sciences name in 2018.
Recommended Stories
- Five stocks we like better than Cassava Sciences
- Hard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
- 2 Utility Stocks May Offer Relief From AI Volatility, But Rates Are the Real Story
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
